Highlights
1. Postmenopausal women with differentiated thyroid cancer (DTC) on long-term TSH suppression therapy showed significantly worse cardiovascular health (LE8 score), higher carotid intima-media thickness, and lower quality-of-life scores than euthyroid controls or hypothyroid patients on replacement therapy.
2. Higher cumulative levothyroxine doses were independently associated with poorer cardiovascular and quality-of-life metrics, while higher TSH levels showed protective associations.
3. The study suggests menopause-specific assessment tools may help guide TSH suppression therapy in postmenopausal DTC survivors to mitigate adverse effects.
Background
Differentiated thyroid carcinoma (DTC) management frequently involves long-term thyroid-stimulating hormone (TSH) suppression therapy to reduce tumor recurrence risk. While current guidelines recommend less aggressive TSH suppression for low-risk patients, many postmenopausal women remain on this therapy for extended periods. The menopause transition itself increases cardiovascular and bone health risks, raising concerns that iatrogenic subclinical hyperthyroidism from TSH suppression may compound these effects. Prior studies have yielded conflicting results about the magnitude of this risk, particularly regarding menopause-specific outcomes.
Study Design
This cross-sectional study compared 107 postmenopausal DTC patients receiving TSH suppression (target TSH < 0.4 mIU/L) for ≥3 years post-total thyroidectomy against two control groups: 80 women on levothyroxine replacement for primary hypothyroidism (target TSH 0.4-4.0 mIU/L) and 97 euthyroid controls. Exclusion criteria included preexisting cardiovascular disease, osteoporosis, or cognitive impairment. Outcomes were assessed using:
- Cardiovascular health: Life’s Essential 8 (LE8) score, carotid intima-media thickness (cIMT)
- Quality of life: Utian QoL Scale (UQoL)
- Cognition: Mini-Mental State Examination
- Body composition: Bioelectrical impedance analysis
- Bone health: Dual-energy X-ray absorptiometry
Key Findings
Compared to both control groups, DTC patients on TSH suppression demonstrated:
- 15.2% lower LE8 scores (68.4 vs. 80.7 in controls; p<0.001)
- 22% worse UQoL scores (p<0.001)
- 0.12 mm greater mean cIMT (p<0.001)
- 2.1-fold higher osteoporosis prevalence (p=0.003)
- 5.3% lower appendicular muscle mass (p=0.017)
Multivariable analysis showed every 1,000 mcg increase in cumulative LT4 dose associated with 0.354-point LE8 score reduction (p<0.001) and 0.396-point UQoL decline (p<0.001). Conversely, each 1 mIU/L TSH increase correlated with improved LE8 (β=0.271) and UQoL (β=0.487) scores.
Expert Commentary
These findings align with emerging evidence that the risks of aggressive TSH suppression may outweigh benefits in postmenopausal DTC survivors, particularly low-risk patients. The novel use of menopause-specific assessment tools provides clinically actionable data to guide therapy de-escalation. Study limitations include the cross-sectional design and potential selection bias from excluding women with preexisting comorbidities.
Conclusion
This study provides the most comprehensive evidence to date that prolonged TSH suppression in postmenopausal DTC survivors adversely impacts multiple menopause-relevant health domains. Clinicians should regularly reassess TSH suppression goals in this population, considering menopause-specific health metrics when making treatment decisions. Further prospective studies are needed to determine whether TSH goal relaxation improves these outcomes.
Funding and Registration
No external funding reported. Not registered at ClinicalTrials.gov.
